Effect of Vitamin D on MS activity by disease-modifying therapy class

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 6, 2015, Pages

  Rotstein, Dalia L ^a   Healy, Brian C ^a,b   Malik, Muhammad T ^a   Carruthers, Robert L ^a   Musallam, Alexander J ^a   Kivisakk, Pia ^a   Weiner, Howard L ^a   Glanz, Bonnie ^a   Chitnis, Tanuja ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CALCIFEDIOL; FINGOLIMOD; GADOLINIUM; GLATIRAMER; VITAMIN D;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; SENSITIVITY ANALYSIS; SURVIVAL; SURVIVAL RATE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 84952881399     PISSN: 23327812     EISSN: None     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000167     Document Type: Article

References (24)

1. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9:599-612.
2. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-2838.
3. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-65.
4. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193-203.
5. Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014;71:306-314.
6. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67:618-624.
7. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012;79:261-266.
8. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008;8:685-698.
9. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009;132: 1146-1160.
10. Stewart N, Simpson S Jr, van der Mei I, et al. Interferonbeta and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012;79:254-260.
11. Loken-Amsrud KI, Holmoy T, Bakke SJ, et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-beta treatment. Neurology 2012;79:267-273.
12. Soilu-Hanninen M, Aivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:565-571.
13. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72: 234-240.
14. Gauthier SA, Glanz BI, Mandel M, Weiner HL. A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev 2006;5:532-536.
15. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-846.
16. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009;66: 54-59.
17. Kappos L, Radue EW, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
18. Bhargava P, Steele S, Cassard S, et al. The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial. Neurology 2014;82(suppl 10):P3.191.
19. Correale J, Ysrraelit MC, Gaitan MI. Vitamin D-mediated immune regulation in multiple sclerosis. J Neurol Sci 2011;311:23-31.
20. Smolders J, Thewissen M, Peelen E, et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 2009;4: e6635.
21. Farias AS, Spagnol GS, Bordeaux-Rego P, et al. Vitamin D3 induces IDO1 tolerogenic DCs and enhances Treg, reducing the severity of EAE. CNS Neurosci Ther 2013; 19:269-277.
22. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
23. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002;59:802-808.
24. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002; 58:S3-S9.